International Index of Erectile Function (IIEF)

Abstract

The International Index of Erectile Function (IIEF) is an internationally recognized, multidimensional, self-administered patient-reported outcome measure (PROM) designed to evaluate male sexual function across distinct diagnostic domains. Developed in 1997 by Raymond C. Rosen and colleagues in conjunction with clinical trials evaluating pharmacotherapies for erectile dysfunction (ED), the instrument addresses the historical absence of standardized, psychometrically validated operationalizations of male sexual functioning. The standard instrument consists of 15 items that assess male sexual function over a 4-week recall period. These items map directly onto five psychometrically robust, empirically derived domains: Erectile Function (6 items), Orgasmic Function (2 items), Sexual Desire (2 items), Intercourse Satisfaction (3 items), and Overall Satisfaction (2 items). Individual items utilize Likert-type scales ranging from 0 (or 1) to 5, allowing for domain-specific subscale scoring and targeted severity categorization, most notably within the Erectile Function domain (score range: 1–30; classifying dysfunction into severe, moderate, mild-to-moderate, mild, and no dysfunction). Psychometric investigations consistently demonstrate exceptional internal consistency across all subscales (Cronbach’s alpha ranging from .73 to .99), robust test-retest reliability (Pearson correlations ranging from .64 to .84 across 4-week intervals), and rigorous convergent, discriminant, and criterion-related validity. Confirmatory and exploratory factor analyses across diverse demographic and clinical populations substantiate its five-factor latent structure. This article provides a comprehensive psychometric review of the IIEF, analyzing its historical context, theoretical models, factor analytic architecture, structural validity, clinical scoring thresholds, and diagnostic utility.

Keywords

International Index of Erectile Function, IIEF, erectile dysfunction, psychometrics, sexual medicine, patient-reported outcome measures, orgasmic function, sexual desire, intercourse satisfaction, urology.

Authors

The International Index of Erectile Function was conceptualized, operationalized, and psychometrically validated by a multidisciplinary international panel of clinical researchers, psychologists, urologists, and biostatisticians led by Raymond C. Rosen, Ph.D.

• Raymond C. Rosen, Ph.D. – Department of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey (UMDNJ), Piscataway, New Jersey, USA; and New England Research Institutes, Watertown, Massachusetts, USA.
• Alan Riley, M.D. – Department of Clinical Psychology and Psychiatry, University of Central Lancashire, Preston, United Kingdom.
• Gorm Wagner, M.D., Ph.D. – Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark.
• Ian H. Osterloh, M.R.C.P. – Pfizer Central Research, Sandwich, Kent, United Kingdom.
• J. Kirkpatrick, B.Sc. – Pfizer Central Research, Sandwich, Kent, United Kingdom.
• A. Mishra, Ph.D. – Pfizer Central Research, Sandwich, Kent, United Kingdom.

Primary author correspondence historically centered through Dr. Raymond C. Rosen, who spearheaded the development and subsequent cross-cultural adaptations of the scale, as well as its abridged iterations such as the IIEF-5 (Sexual Health Inventory for Men [SHIM]).

Purpose

Prior to the late 1990s, the clinical evaluation of erectile dysfunction suffered from profound methodological limitations. Clinical assessments relied disproportionately on invasive objective measurements, such as nocturnal penile tumescence (NPT) monitoring using Rigiscan devices, intracavernous injection testing, or duplex Doppler ultrasound. While these physiological parameters yielded critical diagnostic data regarding vasculogenic or neurogenic integrity, they routinely failed to capture the cognitive, psychological, and relational dimensions of male sexual experience. Concurrently, early clinical trial endpoints were heavily fragmented, utilizing ad-hoc questionnaires lacking psychometric rigor, standardized normative metrics, or established sensitivity to therapeutic change. The advent of efficacious, orally administered phosphodiesterase type 5 (PDE5) inhibitors, specifically sildenafil citrate (Viagra), catalyzed the urgent demand for a standardized, psychometrically validated, multidimensional patient-reported outcome measure.

The primary purpose of the IIEF is to provide a standardized, clinically sensitive, self-administered measurement tool capable of evaluating the spectrum of male sexual function and diagnosing the presence and severity of erectile dysfunction. Designed expressly for clinical practice and international clinical trials, the scale quantifies five fundamental facets of sexual health: erectile performance, orgasmic experience, subjective libido, satisfaction during coitus, and holistic sexual contentment. By delineating these constructs, the IIEF prevents the clinical conflation of primary erectile failure with distinct conditions such as hypoactive sexual desire disorder, premature or delayed ejaculation, or relational dissatisfaction.

In addition to baseline diagnostic staging, the IIEF serves a vital evaluative role as a longitudinal instrument measuring treatment responsiveness. Because its scoring criteria clearly distinguish between normal functioning and graduated tiers of impairment (severe, moderate, mild-to-moderate, and mild ED), clinicians and clinical trial investigators utilize changes in domain scores—particularly the Erectile Function domain—to ascertain therapeutic efficacy, identify minimal clinically important differences (MCID), and adjust pharmacologic, surgical, or psychotherapeutic interventions accordingly.

Psychological Construct

The IIEF measures male sexual functioning not as a monolithic physiological phenomenon, but as an integrated, multidimensional psychological and biological construct. Rooted in modern sexual medicine, the tool operationalizes male sexual health across five interrelated latent dimensions:

1. Erectile Function (EF)

The Erectile Function domain (Items 1, 2, 3, 4, 5, and 15) represents the physiological and psychological apex of penile tumescence and maintenance. This construct does not merely capture binary mechanical ability; it assesses a sequential behavioral process: (a) initiation and frequency of obtaining an erection during sexual activity, (b) rigidity sufficient for vaginal penetration, (c) successful intromission, (d) intra-vaginal maintenance of erection post-penetration, (e) capacity to maintain tumescence to coital completion, and (f) subjective cognitive confidence in acquiring and sustaining an erection. By addressing both somatic rigidity and cognitive appraisals of self-efficacy (e.g., Item 15), the domain bridges physiological capability and psychological readiness, reflecting the profound role that performance anxiety plays in erectile failure.

2. Orgasmic Function (OF)

The Orgasmic Function domain (Items 9 and 10) captures the neurophysiological and sensory culmination of sexual excitation. Item 9 quantifies the frequency of ejaculation during sexual stimulation or intercourse, whereas Item 10 isolates the subjective experience of orgasm or climax (with or without seminal emission). Distinguishing ejaculation from orgasmic sensation is essential in clinical psychometrics, as neurological damage, alpha-blocker therapy, or radical pelvic surgery can decouple emission from sensory climax (e.g., anejaculation, dry orgasm, or retrograde ejaculation). This construct isolates whether the sensory-affective reward pathway remains functionally intact.

3. Sexual Desire (SD)

The Sexual Desire domain (Items 11 and 12) evaluates appetite, libido, and sexual drive. It operationalizes desire as both a behavioral frequency (how often desire is felt) and an affective intensity (subjective rating of the level of desire). Defined explicitly within the instrument as cognitive interest, conscious fantasy, wanting to participate in sexual experiences (masturbation or intercourse), or feeling tension/frustration due to a lack of sexual activity, this construct assesses the baseline motivational engine of sexual activity, separating biological hypoandrogenism or central hypolibido from erectile failure.

4. Intercourse Satisfaction (IS)

The Intercourse Satisfaction domain (Items 6, 7, and 8) examines the experiential quality of partnered penetrative sex. Rather than evaluating mechanical success alone, this domain assesses behavioral frequency of coital attempts, the frequency with which coitus was experienced as satisfactory, and overall enjoyment of intercourse. This construct reflects the hedonic and experiential payoff of the sexual act, addressing the subjective psychological gratification derived specifically from penile-vaginal intercourse.

5. Overall Satisfaction (OS)

The Overall Satisfaction domain (Items 13 and 14) assesses broader evaluative appraisals of the respondent’s sexual life and dyadic relationship. Item 13 measures general satisfaction with one’s overall sex life, while Item 14 examines satisfaction with the sexual relationship with the primary partner. This dimension accounts for the systemic, relational, and emotional contexts of human sexuality, capturing how sexual distress reverberates throughout intimate partnerships and subjective quality of life.

Theoretical Framework

The architectural foundation of the IIEF is deeply anchored in classic and contemporary models of human sexual response, most notably the physiological framework pioneered by William H. Masters and Virginia E. Johnson (1966) and the triphasic psychosomatic model articulated by Helen Singer Kaplan (1974, 1979). Masters and Johnson established the classic four-stage cycle consisting of Excitement, Plateau, Orgasm, and Resolution. While their model provided a foundational biological taxonomy, it omitted the psychological antecedent driving the entire cascade: sexual desire.

Helen Singer Kaplan reformed this physiological paradigm by proposing the Triphasic Concept of Sexual Functioning, comprising three distinct yet interactive phases: Desire, Excitement, and Orgasm. Kaplan demonstrated that distinct neurochemical and psychological systems regulate each phase. Desire is regulated primarily by central neuroendocrine mechanisms (e.g., dopaminergic, serotonergic, and androgenic pathways); excitement is predominantly mediated by parasympathetic and sympathetic peripheral neurovascular mechanisms producing pelvic vasocongestion; and orgasm is governed by sympathetic and somatic spinal reflex arcs. The IIEF maps onto Kaplan’s triphasic model:

• Desire Phase → Measured by the IIEF Sexual Desire domain (Items 11, 12).
• Excitement Phase → Operationalized via the IIEF Erectile Function domain (Items 1–5, 15), reflecting penile tumescence and vascular maintenance.
• Orgasmic Phase → Captured by the IIEF Orgasmic Function domain (Items 9, 10).

Beyond biological staging, the IIEF incorporates the cognitive-affective model of sexual dysfunction developed by David H. Barlow (1986). Barlow’s model posits that erectile dysfunction in psychological contexts is sustained by a vicious cycle of performance anxiety, perceived lack of control, and attentional focus on negative evaluative stimuli (referred to as “spectatoring”) rather than erotic cues. In sexually functional individuals, sexual arousal stimulates positive affect and heightened focus on erotic stimuli, triggering autonomic parasympathetic vasodilation. Conversely, in dysfunctional men, demands for sexual performance trigger anxiety, autonomic sympathetic hyperarousal, vasoconstriction, and catastrophic appraisals of impending failure. By integrating questions regarding confidence (Item 15) and subjective satisfaction (Items 7, 8, 13, 14), the IIEF captures these cognitive-evaluative processes, aligning with Barlow’s conceptualization that affective distress and subjective dissatisfaction are central maintaining features of the disorder.

Validity

The psychometric validity of the IIEF has been extensively corroborated across diverse clinical, non-clinical, and cross-cultural populations, establishing it as the global gold standard for male sexual health assessment.

Content and Face Validity

During the initial development of the instrument by Rosen et al. (1997), content validity was established through rigorous qualitative and quantitative phases. An initial candidate pool of 30 items was extracted from extant clinical inventories, patient interview transcripts, and expert clinical consensus. This pool was submitted to an international panel of urologists, psychologists, endocrinologists, and sex therapists across five countries (the United States, the United Kingdom, France, Germany, and the Netherlands). The items were evaluated for clinical relevance, semantic clarity, cross-cultural equivalence, and domain coverage. Following cognitive debriefing and pilot interviews with ED patients and healthy controls, items were refined into the final 15-item instrument.

Construct and Discriminant Validity

Discriminant validity—the capacity of the instrument to distinguish between individuals with clinically confirmed erectile dysfunction and healthy controls—was definitively established in the primary validation study. Rosen et al. (1997) administered the IIEF to 111 men diagnosed with clinical ED and 109 age-matched, sexually functional control volunteers. Mean scores across all five domains exhibited statistically profound, highly significant differences between groups (p < .001). Specifically, in the Erectile Function domain, the clinical cohort exhibited a mean baseline score of 10.7 (indicating moderate dysfunction), whereas the control group demonstrated a mean score of 25.8 (falling within the functional range). Subsequent receiver operating characteristic (ROC) curve analyses conducted by Cappelleri et al. (1999) indicated that the EF domain possesses remarkable diagnostic accuracy (area under the curve [AUC] > .90), providing clear sensitivity and specificity cutoffs.

Convergent and Criterion Validity

Convergent validity has been repeatedly demonstrated by evaluating correlations between IIEF domain scores and both physiological indices and collateral patient-reported measures. The EF domain correlates robustly with objective physiological diagnostics, including peak systolic velocity and resistive index measured via penile duplex Doppler sonography, as well as Rigiscan rigidity metrics during nocturnal tumescence studies. Furthermore, significant positive correlations are routinely found between IIEF scores and global health-related quality of life measures (e.g., the SF-36 Mental Health and Vitality subscales), while displaying strong negative correlations with measures of depressive symptomatology (e.g., Beck Depression Inventory) and sexual distress inventories.

Sensitivity and Responsiveness to Change

The IIEF exhibits superior sensitivity to treatment-induced clinical changes, making it the premier regulatory endpoint recognized by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for clinical trials in sexual medicine. In multinational, double-blind, placebo-controlled trials of PDE5 inhibitors (such as sildenafil, tadalafil, and vardenafil), patients receiving active therapy demonstrated statistically and clinically significant increases in the EF domain (often shifting 8 to 12 points post-treatment), while placebo arms exhibited minimal movement (typically < 1 to 2 points). Cappelleri et al. (2000) established that a change of 4 or more points on the 30-point EF domain reflects a Minimal Clinically Important Difference (MCID) detectable by patients as a meaningful improvement in functional capacity.

Reliability

The IIEF exhibits exceptional reliability metrics across both internal consistency parameters and temporal stability testing:

Internal Consistency

In the seminal psychometric validation by Rosen et al. (1997), Cronbach’s alpha coefficients demonstrated high internal consistency across all five clinical domains in both patient and control populations:

• Erectile Function: α = .96 (ED cohort) / α = .99 (Control cohort)
• Orgasmic Function: α = .88 (ED cohort) / α = .90 (Control cohort)
• Sexual Desire: α = .82 (ED cohort) / α = .86 (Control cohort)
• Intercourse Satisfaction: α = .87 (ED cohort) / α = .89 (Control cohort)
• Overall Satisfaction: α = .86 (ED cohort) / α = .90 (Control cohort)

Subsequent independent validation studies across international cohorts (e.g., Italian, Spanish, Chinese, Japanese, and Scandinavian translations) have consistently yielded Cronbach’s alpha coefficients exceeding the universally accepted psychometric threshold of .70, with the primary EF domain regularly registering alpha values above .90, demonstrating exceptional item homogeneity.

Test-Retest Stability

Temporal stability was established by administering the instrument to untreated cohorts across a 4-week interval corresponding to the test’s recall period. Pearson product-moment correlation coefficients between baseline and 4-week re-evaluations exhibited strong reproducibility:

• Erectile Function: r = .84 (p < .001)
• Orgasmic Function: r = .78 (p < .001)
• Sexual Desire: r = .76 (p < .001)
• Intercourse Satisfaction: r = .81 (p < .001)
• Overall Satisfaction: r = .64 (p < .001)

These values demonstrate that in the absence of clinical intervention, scores remain stable over time, confirming that the tool is sufficiently robust against transient mood variations while remaining sensitive to genuine therapeutic effects.

Factor Analysis

The structural dimensionality of the IIEF was established using exploratory factor analysis (EFA) and confirmed through structural equation modeling via confirmatory factor analysis (CFA).

Exploratory Factor Analysis (EFA)

During the primary development study (Rosen et al., 1997), principal component analysis (PCA) with orthogonal Varimax rotation was conducted on the candidate items across clinical and non-clinical participants. Factor extraction based on the Kaiser criterion (eigenvalues > 1.0) and scree plot examination unambiguously revealed a five-factor solution accounting for 84% of the total cumulative variance:

• Factor 1 (Erectile Function): Items 1, 2, 3, 4, 5, and 15 loaded uniquely onto this factor with high primary factor loadings ranging from .72 to .91, and negligible cross-loadings (< .30) on secondary factors.
• Factor 2 (Intercourse Satisfaction): Items 6, 7, and 8 demonstrated strong loadings ranging from .74 to .88, isolating the subjective and behavioral quality of penetrative coitus.
• Factor 3 (Orgasmic Function): Items 9 and 10 demonstrated definitive loadings of .89 and .92, cleanly delineating ejaculation and orgasmic sensation.
• Factor 4 (Sexual Desire): Items 11 and 12 loaded at .85 and .89, confirming the independence of libido from mechanical tumescence.
• Factor 5 (Overall Satisfaction): Items 13 and 14 clustered at .81 and .87, isolating relational and global sexual life satisfaction.

Confirmatory Factor Analysis (CFA)

To verify the generalizability of this five-factor latent structure, Cappelleri et al. (1999) performed confirmatory factor analysis on a large multinational sample of over 1,000 men enrolled in clinical trials. The hypothesized five-factor model demonstrated exceptional goodness-of-fit indices across diverse populations:

• Comparative Fit Index (CFI): > .95
• Tucker-Lewis Index (TLI): > .94
• Root Mean Square Error of Approximation (RMSEA): < .06
• Standardized Root Mean Square Residual (SRMR): < .05

Multi-group CFA evaluations have further established structural metric and scalar invariance across diverse age cohorts (e.g., younger vs. older men) and international translations, confirming that the IIEF measures identical psychological and physiological constructs regardless of cultural or linguistic contexts.

Instrument / Measurement Tool

• Instrument Type: Standardized, self-administered patient-reported outcome measure (PROM).
• Administration Format: Paper-and-pencil, computerized, or digital online questionnaire.
• Target Population: Adult men (aged 18 and older) who are sexually active and engaging in, or attempting, sexual activity or intercourse.
• Recall Timeframe: The preceding 4 weeks.
• Total Number of Items: 15 items.
• Domain Classification:
  • Erectile Function: Items 1, 2, 3, 4, 5, and 15 (Score range: 1–30)
  • Orgasmic Function: Items 9 and 10 (Score range: 0–10)
  • Sexual Desire: Items 11 and 12 (Score range: 2–10)
  • Intercourse Satisfaction: Items 6, 7, and 8 (Score range: 0–15)
  • Overall Satisfaction: Items 13 and 14 (Score range: 2–10)
• Scoring and Response Scale:
  • Items are scored using Likert-type scales ranging from 0 to 5 or 1 to 5.
  • A score of 0 is typically designated for individuals reporting no sexual activity or no intercourse attempts during the 4-week window (e.g., Items 1, 2, 3, 4, 5, 6, 7, 8, 9, 10).
  • Items 11, 12, 13, 14, and 15 are scored on a 1-to-5 scale, as subjective desire, confidence, and general satisfaction exist independently of recent sexual encounters.
  • Domain scores are computed by summing the raw scores of the items belonging to that domain. A total composite score (range: 5–75) can mathematically be derived, but is clinically discouraged in favor of domain-specific profiles.
• Diagnostic Stratification for Erectile Dysfunction:

  Severity of erectile dysfunction is classified via the Erectile Function (EF) domain score (Items 1–5 + 15), established by Cappelleri et al. (1999):

  • Severe Erectile Dysfunction: Scores 1 to 10
  • Moderate Erectile Dysfunction: Scores 11 to 16
  • Mild-to-Moderate Erectile Dysfunction: Scores 17 to 21
  • Mild Erectile Dysfunction: Scores 22 to 25
  • No Erectile Dysfunction (Normal Function): Scores 26 to 30
• Completion Time: Approximately 5 to 10 minutes.

Permissions & Fee and Test Year

The International Index of Erectile Function was developed in 1997 by Raymond C. Rosen et al., funded in part by Pfizer Inc. during clinical trials for sildenafil citrate. The original research publication appeared in the journal Urology (Volume 49, Issue 6, June 1997, Pages 822–830).

Copyright and Usage Terms:

• Non-Commercial Clinical and Academic Research: The instrument is widely accessible and may be used by clinicians and academic researchers without payment of royalty fees, provided proper citation of the original 1997 publication is maintained and no changes are made to the item phrasing, response categories, or scoring algorithms.
• Commercial and Pharmaceutical Clinical Trials: For sponsored, commercial, or for-profit pharmaceutical studies, licensing, translation certifications, and electronic implementation clearances (eCOA/ePRO) are managed through clinical outcome assessment repositories and relevant copyright holders (such as the Mapi Research Trust / PROQOLID database).

References

• Barlow, D. H. (1986). Causes of sexual dysfunction: The role of anxiety and cognitive interference. Journal of Consulting and Clinical Psychology, 54(2), 140–148. https://doi.org/10.1037/0022-006X.54.2.140
• Cappelleri, J. C., Rosen, R. C., Smith, M. D., Mishra, A., & Osterloh, I. H. (1999). Diagnostic potential of the International Index of Erectile Function. Urology, 54(2), 346–351. https://doi.org/10.1016/s0090-4295(99)00155-2
• Cappelleri, J. C., Siegel, R. L., Osterloh, I. H., & Rosen, R. C. (2000). Relationship between patient self-assessment of erectile function and the erectile function domain of the International Index of Erectile Function. Urology, 56(3), 477–481. https://doi.org/10.1016/s0090-4295(00)00697-5
• Kaplan, H. S. (1974). The New Sex Therapy: Active Treatment of Sexual Dysfunctions. Brunner/Mazel.
• Kaplan, H. S. (1979). Disorders of Sexual Desire and Other New Concepts and Techniques in Sex Therapy. Brunner/Mazel.
• Masters, W. H., & Johnson, V. E. (1966). Human Sexual Response. Little, Brown and Company.
• Rosen, R. C., Cappelleri, J. C., & Gendrano, N. (2002). The International Index of Erectile Function (IIEF): A state-of-the-science review. International Journal of Impotence Research, 14(4), 226–244. https://doi.org/10.1038/sj.ijir.3900857
• Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997). The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology, 49(6), 822–830. https://doi.org/10.1016/S0090-4295(97)00238-0

13. Items of the Scale (Questionnaire)